-+ 0.00%
-+ 0.00%
-+ 0.00%

Cellectis Presents Research Data On TALEN And TALEB Technologies For Gene And Cellular Therapies At ASGCT Annual Meeting

Benzinga·04/28/2025 20:33:50
Listen to the news

Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today unveils research data on TALEN®-mediated non-viral transgene insertion for advancing cellular and gene therapies, and advancements in genetic editing using TALE base editors (TALEB), at the Society of Gene and Cell Therapy (ASGCT) annual meeting, that will be held on May 13-17, 2025 in New Orleans.